Animal biotechnology

In short

Animal biotechnology is the use of molecular, reproductive and cell-level tools on animals - to breed them faster (artificial insemination, embryo transfer, IVF, sexed semen), to copy them (nuclear transfer cloning), to change their genome (transgenesis and gene editing), and to use them as factories or models (recombinant proteins in milk, vaccines, knockout mice for drug testing). It matters because India has the world's largest cattle and buffalo population and the largest milk output, so a few percent gain in reproductive efficiency is worth thousands of crores, and because every new drug in India must pass animal studies before human trials. It is examined in B.Sc/M.Sc biotechnology, animal biotechnology and GATE BT (XL/BT life-science papers), and applied at ICAR-NDRI Karnal, ICAR-IVRI Izatnagar, NIAB Hyderabad, NDDB, and at Indian Immunologicals, Hester Biosciences, Bharat Biotech, Biocon and CRO animal facilities (Syngene, Vimta, Aurigene). Work here is legally gated by the CCSEA (formerly CPCSEA) and institutional animal ethics committees.

Explained

Scope, terms and the starting materials

• Animal biotechnology covers reproductive technology, cloning, transgenesis/editing, animal-derived biologicals and animal models. Animal cell culture technique itself is the enabling platform; here the focus is the whole animal and the embryo.
• Gamete and embryo stages: oocyte (arrested at metaphase II when ovulated) → zygote → 2/4/8-cell → morula → blastocyst (inner cell mass + trophectoderm). Transfer to a recipient is usually at morula/blastocyst (day 6-8 in cattle).
• Totipotent (can form a whole organism + placenta - zygote, early blastomeres), pluripotent (all three germ layers - embryonic stem cells, iPSCs), multipotent (one lineage - haematopoietic stem cells).
• Chimaera: an animal made of cells from two genomes (e.g. ES-cell injected blastocyst). Mosaic: one genome with two genotypes arising after fertilisation. Transgenic: carries a stably integrated foreign gene in the germ line.
• Germ-line change is heritable; somatic change is not - the single most tested distinction.

Assisted reproductive technologies in livestock

• Artificial insemination (AI): semen collected (artificial vagina/electro-ejaculation), evaluated for volume, concentration (photometer), progressive motility and morphology, diluted in an extender (egg-yolk-citrate or Tris-egg-yolk, with glycerol as cryoprotectant and antibiotics), filled into 0.25 mL French straws, equilibrated, frozen over liquid-nitrogen vapour and stored at −196 °C. One bull can serve tens of thousands of cows a year.
• Why AI: rapid spread of proven superior sires, disease control, no bull to maintain, pedigree records. Limits: needs trained technicians and an unbroken LN₂ cold chain; poor heat detection is the main cause of failure in field conditions.
• Oestrus synchronisation: prostaglandin F2α (lyses the corpus luteum) or progesterone devices (CIDR) + GnRH, so a group can be bred on a fixed schedule ("fixed-time AI").
• Superovulation and MOET (Multiple Ovulation and Embryo Transfer): donor given FSH (descending doses over 4 days) or PMSG/eCG → multiple ovulations; inseminated; embryos recovered non-surgically on day 7 by flushing the uterine horns with a Foley catheter; graded; transferred fresh or frozen to synchronised recipients. Gets many calves a year from one elite cow instead of one.
• OPU-IVF (ovum pick-up with in-vitro embryo production): oocytes aspirated from follicles by ultrasound-guided needle, matured in vitro (IVM, ~24 h), fertilised in vitro (IVF with capacitated, heparin-treated sperm) or by ICSI, cultured ~7 days to blastocyst, then transferred. This is the technology in India's IVF-ET centres under the Rashtriya Gokul Mission for multiplying indigenous breeds (Gir, Sahiwal, Red Sindhi, Murrah).
• Sexed semen: X- and Y-bearing sperm separated by flow cytometry after Hoechst 33342 staining (X sperm hold ~3.8-4.2% more DNA in cattle), giving ~90% female calves. Used to raise heifer numbers in dairy herds; conception rate is typically a few points below conventional semen, and dose size is smaller (~2-4 million sperm).
• Embryo splitting (micromanipulation twinning): a blastocyst bisected with a microblade gives identical twins - the cheapest "cloning".
• Cryopreservation: slow freezing with glycerol/ethylene glycol, or vitrification (very high cryoprotectant, ultra-rapid cooling, no ice crystals) in open-pulled straws for oocytes and embryos. Semen, embryos and somatic cells of threatened breeds are banked at ICAR-NBAGR, Karnal.

Cloning by nuclear transfer

• Definition: producing an animal genetically identical to a donor by transferring a donor nucleus into an enucleated oocyte.
• SCNT steps: (1) recover and mature oocytes; (2) enucleate by micromanipulation (remove MII plate + first polar body); (3) place a quiescent (serum-starved, G0) donor somatic cell - fibroblast, granulosa, ear-skin cell - under the zona; (4) electrofusion and activation (Ca²⁺ ionophore/ionomycin + 6-DMAP, or ethanol); (5) culture to blastocyst; (6) transfer to a synchronised surrogate; (7) verify by microsatellite/STR genotyping.
• Handmade cloning (zona-free; devised by Vajta's group in Denmark, 2001, and adapted by NDRI for buffalo): the zona is digested with pronase, the oocyte bisected with a hand-held blade, the enucleated half fused with a donor cell - no micromanipulator, far cheaper. Used for India's cloned buffaloes.
• Landmarks: *Dolly* the sheep (1996, Roslin Institute - first mammal from an adult somatic cell); then cattle, goat, pig, cat, dog, horse, camel. India: *Samrupa* (2009, ICAR-NDRI Karnal - first cloned buffalo calf, died within days), *Garima* and *Garima-II* (2009-10), cloned Murrah bulls; *Noori*, the first cloned Pashmina goat (SKUAST-Kashmir, 2012); cloned camel work in the Gulf.
• Why efficiency is low (typically <1-5% live births per reconstructed embryo): incomplete epigenetic reprogramming of the somatic nucleus - residual DNA methylation and histone marks, faulty imprinting, X-inactivation errors - plus mitochondrial heteroplasmy from the recipient oocyte.
• Large offspring syndrome / abnormal placentation, hydrallantois, respiratory failure at birth and shortened telomeres are reported complications.
• Reproductive cloning makes an animal; therapeutic cloning makes a patient-matched blastocyst for ES cells - now largely superseded by iPSCs (Yamanaka factors Oct4, Sox2, Klf4, c-Myc), which avoid embryo use.

Transgenic animals: how they are made and why

Routes, in the order examined:

1. Pronuclear microinjection: linear DNA injected into the larger male pronucleus of a zygote; random integration as multicopy tandem arrays; simple but low efficiency (~1-4% of born pups transgenic) and prone to mosaicism and position effects. Classic for mice.
2. Retroviral/lentiviral vectors: infect embryos or stem cells; efficient integration but small insert size and mosaicism.
3. ES-cell mediated (gene targeting): construct electroporated into mouse ES cells, selected (neo⁺/positive-negative selection with HSV-tk), correctly targeted clones injected into a blastocyst → chimaera → breed for germ-line transmission. The route to knockouts.
4. SCNT-mediated transgenesis: edit/transfect the somatic cell line in vitro, screen clones, then clone the verified cell - gives non-mosaic founders and works in livestock where ES cells are unavailable. This is how most transgenic cattle, goats and pigs are made.
5. Sperm-mediated gene transfer and testis-mediated / spermatogonial stem-cell transfer - simple, variable.
6. Gene editing (below), now the dominant method.
7. Transgene design: promoter (tissue-specific - β-casein or β-lactoglobulin for mammary expression), signal peptide, cDNA with intron, polyadenylation signal, insulators/matrix-attachment regions to reduce silencing; verification by PCR, Southern blot (copy number), RT-PCR/qPCR, Western blot, and breeding tests for germ-line transmission.
8. Conditional systems: Cre-loxP (tissue-specific knockout), Flp-FRT, tetracycline-inducible (Tet-on/Tet-off) - needed when a gene is embryonic-lethal.
9. Products and traits: recombinant protein in milk (pharming), faster growth (AquAdvantage salmon), disease resistance (mastitis-resistant cattle expressing lysostaphin; PRRS-resistant pigs), low-allergen or high-casein milk, hornless (polled) cattle, GalSafe pigs for xenotransplantation and allergen-free meat.

Gene editing, knockouts and animal models

• Editing tools in order of development: ZFNs (zinc-finger nuclease + FokI dimer) → TALENs → CRISPR-Cas9 (guide RNA + Cas9 cuts at a 20-nt target next to a PAM). Repair by NHEJ gives indels → knockout; HDR with a donor template gives knock-in/precise edits. Base editors and prime editors avoid double-strand breaks.
• Delivery to embryos: cytoplasmic/pronuclear microinjection of Cas9 mRNA + gRNA, or electroporation of ribonucleoprotein; founders are often mosaic, so F1 breeding establishes the line.
• Mendelian breeding of a line: heterozygous founder × wild type → F1 50% het; het × het → 1 wild : 2 het : 1 homozygous null, so one in four pups is the knockout; genotype every pup by PCR.
• Standard models: nude (Foxn1^nu) mice - no thymus, no T cells, accept xenografts; SCID and NOD-SCID/NSG - for human tumour and immune-system grafting; knockout mice (p53, ApoE for atherosclerosis, db/db and ob/ob for diabetes/obesity); knock-in and humanised mice; transgenic rats, zebrafish, *Drosophila* and *C. elegans* as lower models; oncomouse for carcinogenicity.
• Uses of models: gene function, disease mechanism, pharmacokinetics, toxicology (acute, sub-chronic, reproductive), vaccine potency and safety, biosimilar comparability.
• Limitations: mouse physiology ≠ human; genetic background effects; compensation by paralogous genes; cost and ethics.

Animal pharming, veterinary biologicals and xenotransplantation

• Pharming (gene farming): the animal is the bioreactor. Milk is preferred - high protein output, easy harvest, mammary post-translational modification. ATryn (recombinant human antithrombin from transgenic goat milk) was the first such approved product; Ruconest/Rhucin (C1 esterase inhibitor) comes from transgenic rabbit milk. Also explored: urine, blood, egg white (transgenic hens), silkworm cocoon.
• Advantages over microbial systems: correct glycosylation and folding of complex human proteins, gram-per-litre yields, low capital cost. Limits: long generation interval, risk of prion/viral contamination, non-human glycans (α-Gal, NeuGc) causing immunogenicity, regulatory burden, variable expression between founders.
• Veterinary biologicals (large Indian industry): FMD vaccine (banked antigen, trivalent O/A/Asia-1 - IVRI/Indian Immunologicals, under the National Animal Disease Control Programme), HS, BQ, brucellosis, PPR and classical swine fever vaccines, rabies, Newcastle disease and the Lumpy skin disease vaccine "Lumpi-ProVacInd" (ICAR-NRCE/IVRI). Diagnostics: ELISA kits, lateral-flow and PCR panels for FMD, brucellosis, mastitis.
• Antibody and protein sources: polyclonal antisera and anti-snake-venom serum raised in horses; heparin and insulin historically from animal tissue; monoclonal antibodies via hybridoma (covered under immunology).
• Xenotransplantation: pig organs engineered to delete α-1,3-galactosyltransferase (GGTA1), CMAH, B4GALNT2 and to add human complement regulators (CD46/CD55) and thromboregulatory genes, with PERV inactivation; pig kidney and heart transplants into humans have been done experimentally. Pig heart valves and porcine insulin/skin dressings are already routine.

Indian regulation, ethics and the 3Rs

• Prevention of Cruelty to Animals Act, 1960 is the parent law. The regulator, formerly CPCSEA, is now the Committee for Control and Supervision of Experiments on Animals (CCSEA), constituted under this Act; the operative rules are the Breeding of and Experiments on Animals (Control and Supervision) Rules, 1998 (amended 2001 and later).
• Every institution using animals must be CCSEA-registered, must run an IAEC (Institutional Animal Ethics Committee) with a CCSEA-nominated main nominee and a non-scientific member, and must obtain IAEC approval (Form B style protocol) before procurement. Large-animal and certain re-use/withdrawal cases need CCSEA permission. Records, housing standards, anaesthesia/analgesia, humane end-points and euthanasia methods are prescribed.
• The 3Rs (Russell and Burch): Replacement (cell lines, organoids, in-silico, *in-chemico*), Reduction (fewer animals, better statistics), Refinement (less pain and distress). Indian rules have progressively moved towards replacement - cosmetics testing on animals (banned 2014) and import of animal-tested cosmetics (banned from November 2014) were first prohibited under the Drugs and Cosmetics Rules, 1945 and are carried forward in the Cosmetics Rules, 2020, which now govern cosmetics, and the New Drugs and Clinical Trials (Amendment) Rules, 2023 allow non-animal and human-relevant methods for drug safety/efficacy where scientifically justified. The exact scope is being operationalised, so check the current rule text before relying on it.
• Genetic modification: transgenic animals are GMOs under the Environment (Protection) Act, 1986 and the Rules, 1989 for manufacture, use, import, export and storage of hazardous micro-organisms/GE organisms. Oversight ladder: IBSC (institute) → RCGM (DBT) → GEAC (MoEFCC) for environmental release; DBT guidelines cover recombinant DNA research and transgenic animal work.
• Stem cells: the National Guidelines for Stem Cell Research (ICMR-DBT, 2017) govern human/animal stem-cell work; germ-line editing of human embryos for reproduction is prohibited.
• Other relevant instruments: Wild Life (Protection) Act, 1972 and CITES for wild species and primates; Biological Diversity Act, 2002 and its 2023 amendment for access to Indian biological resources and benefit sharing; Livestock Importation Act for germplasm import; Food Safety and Standards Act for products of animal origin.

Key points

• Germ-line vs somatic - only a germ-line change is inherited; transgenic status requires germ-line transmission.
• AI multiplies a superior sire; one ejaculate gives hundreds of 0.25 mL straws stored at −196 °C in liquid nitrogen.
• Superovulation + MOET multiplies the female contribution - embryos flushed non-surgically on day 7.
• OPU-IVF = oocyte aspiration, IVM → IVF → blastocyst → transfer; India's Gokul Mission IVF-ET centres use it on indigenous breeds.
• Sexed semen separates X/Y sperm by flow cytometry using a ~4% DNA difference; ~90% female calves.
• Vitrification beats slow freezing for oocytes and blastocysts because it avoids ice-crystal damage.
• SCNT = enucleated MII oocyte + quiescent (G0) somatic cell, electrofusion, chemical activation, surrogate transfer.
• Dolly (1996) proved adult somatic nuclei can be reprogrammed; Indian firsts are *Samrupa*/*Garima* (buffalo, NDRI) and *Noori* (Pashmina goat).
• Cloning efficiency is low mainly because epigenetic reprogramming is incomplete - not because the DNA is wrong.
• Pronuclear microinjection gives random multicopy integration; ES-cell targeting gives precise knockouts; SCNT of edited cells gives non-mosaic livestock founders.
• Cre-loxP and Tet systems give conditional/inducible knockouts when the gene is essential for development.
• CRISPR-Cas9: NHEJ repair → knockout; HDR with donor → knock-in.
• Het × het gives 1:2:1, so 25% homozygous nulls - the basis of every knockout breeding scheme.
• Nude and NSG mice are immunodeficient hosts for human tumour xenografts.
• Pharming expresses human proteins in milk under a mammary promoter (β-casein, β-lactoglobulin); ATryn from goat milk was the first approved.
• CCSEA (ex-CPCSEA) + IAEC approval under the PCA Act, 1960 and the 1998 Rules is mandatory before any animal experiment in India.
• Transgenic animals are GMOs - IBSC → RCGM → GEAC under the EPA 1986 Rules, 1989.
• 3Rs - Replacement, Reduction, Refinement - are the ethical frame examiners expect you to name.

Formulas and examples

1. Semen dilution for AI. A Murrah bull gives 5 mL of semen at 1,200 million sperm/mL with 70% progressive motility. Doses of 20 million motile sperm in 0.25 mL straws are wanted.

• Total sperm = 5 × 1,200 = 6,000 million. Motile = 6,000 × 0.70 = 4,200 million.
• N = 4,200 / 20 = 210 straws.
• Total extended volume = 210 × 0.25 = 52.5 mL → extender to add = 52.5 − 5 = 47.5 mL (dilution ≈ 1:9.5).
• If 10% of straws fail post-thaw quality checks, usable straws = 189.

2. MOET output versus natural breeding. A donor cow is flushed 6 times a year, averaging 10 embryos per flush, 70% transferable, and transferred embryos give a 50% pregnancy rate.

• Embryos = 6 × 10 = 60; transferable = 60 × 0.70 = 42; calves = 42 × 0.50 = 21 calves/year.
• Naturally she would produce about 1 calf/year → a 21-fold gain in female genetic multiplication.
• If each transfer costs ₹6,000 (illustrative: hormones, flushing, recipient synchronisation, technician), cost per calf = 42 × 6,000 / 21 = ₹12,000 per calf.

3. SCNT efficiency. 450 oocytes are enucleated and reconstructed; 310 cleave; 72 reach blastocyst; 40 are transferred into 20 recipients; 6 become pregnant; 2 live calves are born.

• Cleavage rate = 310/450 = 68.9%; blastocyst rate = 72/450 = 16.0%.
• Pregnancy rate per recipient = 6/20 = 30%; per embryo transferred = 6/40 = 15%.
• Overall cloning efficiency = 2/450 = 0.44% (calves per reconstructed embryo); 2/40 = 5% per embryo transferred - quote the denominator you mean, since both numbers are "efficiency".

4. Knockout mouse breeding. Het × het cross; p(homozygous null) = 0.25.

• In a litter of 8, expected nulls = 8 × 0.25 = 2.
• For ≥1 null with 95% confidence: n ≥ ln(0.05)/ln(0.75) = (−2.9957)/(−0.2877) = 10.4 → genotype at least 11 pups.
• At about 1 null per 4 pups, obtaining a breeding pair of nulls needs roughly 8 pups on average - two litters.

5. Yield from a pharming goat. A transgenic goat secretes 2.5 g/L of a human protein in milk; lactation yield 800 L; purification recovery 50%; final product dose 10 mg.

• Crude protein = 2.5 × 800 = 2,000 g = 2.0 kg. Purified = 2,000 × 0.50 = 1,000 g = 1.0 kg.
• Doses = 1,000 g / 0.010 g = 1,00,000 doses from one animal per lactation.
• An *E. coli* or CHO route would need a multi-thousand-litre bioreactor campaign for the same mass - and *E. coli* could not glycosylate it at all.

Where it is used

• Dairy and livestock improvement: NDDB and State semen stations (frozen semen, sexed semen), ICAR-NDRI Karnal and ICAR-CIRB Hisar (cloning, MOET), IVF-ET centres under the Rashtriya Gokul Mission, ICAR-NBAGR germplasm bank - roles: embryo transfer technologist, AI technician trainer, semen station QC analyst.
• Veterinary vaccines and diagnostics: Indian Immunologicals (Hyderabad), Hester Biosciences, Biovet, ICAR-IVRI - FMD, brucellosis, PPR, lumpy skin disease vaccines and ELISA/PCR kits; roles in QC, potency testing and animal-house management.
• Pharma and CRO preclinical work: Biocon, Sun Pharma, Dr Reddy's, Syngene, Vimta, Aurigene - toxicology and efficacy studies in CCSEA-registered facilities; roles: study director, laboratory animal technician, IAEC coordinator, regulatory affairs.
• Research animal facilities and models: NII and ICGEB Delhi, NCBS-inStem-BLiSC Bengaluru, NIAB and CCMB Hyderabad, NIPER and IISc - transgenic and knockout mouse lines, gene-function and disease studies.
• Biologicals from animals: anti-snake-venom serum (horses) at Haffkine, Bharat Serums, Premium Serums; porcine heart valves and heparin; silkworm and sericulture biotechnology.
• Wildlife and conservation: gene banking and cloning research for threatened Indian breeds and species, and biodiversity compliance work under the Biological Diversity Act.

Interview questions

• Q: What is the difference between a transgenic and a cloned animal? A: A transgenic animal carries a foreign or edited gene in its germ line; a clone has an unaltered genome that is simply a copy of a donor's nuclear DNA. An animal can be both when an edited cell line is used for SCNT.
• Q: Why is the donor cell starved into G0 before nuclear transfer? A: Quiescence helps synchronise the donor nucleus with the recipient oocyte's cell-cycle state and improves reprogramming and ploidy fidelity.
• Q: Is a clone 100% identical to its donor? A: No - mitochondrial DNA comes from the recipient oocyte, and epigenetic marks, imprinting and coat-pattern or environmental effects differ, so phenotypes diverge.
• Q: Why is cloning efficiency so low? A: The somatic nucleus is incompletely reprogrammed; residual DNA methylation and histone marks, faulty imprinting and abnormal placentation cause most embryonic and perinatal losses.
• Q: Why are ES cells not used for making transgenic cattle? A: Germ-line-competent ES cell lines have not been reliably established in cattle, so livestock transgenesis goes through somatic cell editing followed by SCNT.
• Q: How are X- and Y-bearing sperm separated? A: By flow cytometry after DNA staining with Hoechst 33342 - the X sperm contain about 4% more DNA and fluoresce more brightly, so droplets are charged and deflected accordingly.
• Q: Why is milk the preferred tissue for recombinant protein expression? A: Mammary epithelium secretes grams per litre with mammalian folding and glycosylation, the fluid is harvested non-invasively and repeatedly, and tissue-specific promoters such as β-casein restrict expression there.
• Q: What is a conditional knockout and why would you need one? A: A gene flanked by loxP sites is deleted only where Cre recombinase is expressed - essential when a straight knockout is embryonic-lethal or when you want tissue- or time-specific loss.
• Q: Which approvals are needed in India before starting a mouse experiment? A: The institution must be CCSEA-registered and the protocol approved by its IAEC under the PCA Act, 1960 and the 1998 Rules; transgenic animals additionally go through IBSC and RCGM, and environmental release through GEAC.
• Q: State the 3Rs with one example each. A: Replacement - use a validated cell-based assay instead of a rabbit pyrogen test; Reduction - power the study statistically to use fewer animals; Refinement - use analgesia and humane end-points to limit suffering.
• Q: What is the main immunological barrier in pig-to-human xenotransplantation? A: Pre-existing human antibodies against the α-Gal epitope cause hyperacute rejection, which is why GGTA1 (and CMAH, B4GALNT2) are knocked out and human complement regulators added.
• Q: If a CRISPR founder mouse is mosaic, how do you establish a clean line? A: Breed the founder to wild type, genotype and sequence F1 offspring to pick a single defined allele transmitted through the germ line, then intercross F1 heterozygotes.

Common mistakes

• Calling SCNT "cloning a gene" - gene cloning is molecular; animal cloning is nuclear transfer into an enucleated oocyte.
• Forgetting mitochondrial DNA and epigenetics when claiming a clone is identical.
• Treating a transfected or injected founder as transgenic without proving germ-line transmission and copy number.
• Using total sperm instead of motile sperm in dose calculations, or forgetting that the extender volume includes the original semen.
• Quoting a cloning "efficiency" without saying whether the denominator is reconstructed embryos, embryos transferred or recipients.
• Assuming a knockout cross gives a homozygote in every litter of four - 25% is an expectation, so genotype 11+ pups for 95% confidence.
• Writing "CPCSEA permission" for routine small-animal work when it is the IAEC that approves protocols in a CCSEA-registered facility, and ignoring the separate GEAC/RCGM route for transgenics.

Related topics

Cell culture techniques · Recombinant DNA technology · Immunology and ELISA · PCR and DNA sequencing · Stem cells and regenerative medicine · Bioethics, biosafety and IPR in biotechnology